Investigation of the Effectiveness of Nutrition at the Molecular Level in Patients with Sepsis

Hamit Yıldız; Türkay Güncü

doi:10.58600/eurjther2291

Authors

Hamit Yıldız Department of Internal Medicine, Faculty of Medicine, Gaziantep University, Gaziantep, Turkiye https://orcid.org/0000-0001-7858-5123
Türkay Güncü SANOVEL Ilac AS., Istanbul, Turkiye https://orcid.org/0000-0002-0223-7314

DOI:

https://doi.org/10.58600/eurjther2291

Keywords:

Sepsis, Biomarker, Kallistatin, Plasminogen Activator Inhibitor-1, Nesfatin-1, High Mobility Group Box-1, protein diet

Abstract

Objective: The aim of this study was to compare inflammatory and anti-inflammatory molecule levels in sepsis patients receiving normal (1.3 mg/kg/day) and high (2 mg/kg/day) protein supplementation.

Methods: Two groups of patients were compared based on protein supplementation: normal (1.3 mg/kg/day) and high (2 mg/kg/day). Levels of kallistatin, nesfatin-1, plasminogen activator inhibitor-1 (PAI-1), and high mobility group box-1 (HMGB-1) were measured. Disease severity was assessed using APACHE II, SAPS, and SOFA scores.

Results: Demographic characteristics and intensive care scores were similar between groups (p>0.05). Group 1 had significantly higher 0-hour levels of HMGB-1, kallistatin, PAI-1, and nesfatin-1 compared to 24 and 48 hours (p<0.001). Group 2 had higher 0-hour levels, but changes were not significant (p>0.05)

Conclusions: High-dose protein feeding in sepsis patients may not suppress inflammation-related protein synthesis despite the presence of oxidative damage and muscle catabolism.

Metrics

Metrics Loading ...

References

Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC (2016) The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315:801-810. https://doi.org/10.1001/jama.2016.0287

Enguix-Armada A, Escobar-Conesa R, Garcia-De La Torre A, De La Torre-Prados MV (2016) Usefulness of several biomarkers in the management of septic patients: C-reactive protein, procalcitonin, presepsin and mid-regional pro-adrenomedullin. Clin Chem Lab Med 54:163-168. https://doi.org/10.1515/cclm-2015-0243

Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546-1554. https://doi.org/10.1056/NEJMoa022139

Elixhauser A, Friedman B, Stranges E (2006) Septicemia in U.S. Hospitals, 2009. Agency for Healthcare Research and Quality (US), Rockville (MD)

. Agency for Healthcare Research and Quality, Rockville, MD http://www.hcup- us.ahrq.gov/reports/statbriefs/sb122.pdf (Accessed on August 01, 2013)

Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R (2014) Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 311:1308-1316. https://doi.org/10.1001/jama.2014.2637

Esper AM, Martin GS (2009) Extending international sepsis epidemiology: the impact of organ dysfunction. Crit Care 13:120. https://doi.org/10.1186/cc7704

Goldenberg NM, Steinberg BE, Slutsky AS, Lee WL (2011) Broken barriers: a new take on sepsis pathogenesis. Sci Transl Med 3:88ps25. https://doi.org/10.1126/scitranslmed.3002011

. Marshall JC, Vincent JL, Guyatt G, et al. Outcome measures for clinical research in sepsis: a report of the 2nd Cambridge Colloquium of the International Sepsis Forum. Crit Care Med 2005; 33: 1708-1716.

. Melamed A, Sorvillo FJ. The burden of sepsis-associated mortality in the United States from 1999 to 2005: an analysis of multiple-cause-of-death data. Crit Care 2009; 13: R28 [PMID: 19250547 DOI: 10.1186/cc7733].

. American Cancer Society, Surveillance Research. Estimated New Cancer Cases and Deaths by Sex for All Sites, US, 2011.

. Bloch KC. Infectious Diseases. In: McPhee SJ, Hammer GD: Pathophysiology of Disease. New York: McGraw-Hill, 2010: 57-83.

. Borgen L. Total parenteral nutrition in adults. Am J Nurs 1978; 78: 224-228.

. Hurt RT, McClave SA, Martindale RG, Ochoa Gautier JB, Coss-Bu JA, Dickerson RN, Heyland DK, Hoffer LJ, Moore FA, Morris CR, et al. Summary points and consensus recommendations from the international protein summit. Nutr Clin Pract. 2017;32(1 Suppl):142S–51S.

. Puthucheary ZA, Rawal J, McPhail M, Connolly B, Ratnayake G, Chan P, Hopkinson NS, Phadke R, Dew T, Sidhu PS, et al. Acute skeletal muscle wasting in critical illness. JAMA. 2013;310(15):1591–600.

. Burd, N.A.; Gorissen, S.H.; van Loon, L.J. Anabolic resistance of muscle protein synthesis with aging. Exerc. Sport Sci. Rev. 2013, 41, 169–173.

. Dickinson, J.M.; Volpi, E.; Rasmussen, B.B. Exercise and nutrition to target protein synthesis impairments in aging skeletal muscle. Exerc. Sport Sci. Rev. 2013, 41, 216– 223.

. Deutz, N.E.; Wolfe, R.R. Is there a maximal anabolic response to protein intake with a meal? Clin. Nutr. 2013, 32, 309–313.).

. Mamerow, M.M.; Mettler, J.A.; English, K.L.; Casperson, S.L.; Arentson-Lantz, E.; Sheffield-Moore, M.; Layman, D.K.; Paddon-Jones, D. Dietary protein distribution positively influences 24-h muscle protein synthesis in healthy adults. J. Nutr. 2014, 144, 876–880

. Paddon-Jones, D.; Leidy, H. Dietary protein and muscle in older persons. Curr. Opin. Clin. Nutr. Metab. Care 2014, 17, 5–11

. Luiking, Y.C.; Deutz, N.E.; Memelink, R.G.; Verlaan, S.; Wolfe, R.R. Postprandial muscle protein synthesis is higher after a high whey protein, leucine-enriched supplement than after a dairy-like product in healthy older people: A randomized controlled trial. Nutr. J. 2014, 13, 9.

. Thalacker-Mercer, A.E.; Drummond, M.J. The importance of dietary protein for muscle health in inactive, hospitalized older adults. Ann. N. Y. Acad. Sci. 2014, 1328, 1–9)

. Hoffer LJ, Bistrian BR. Why critically ill patients are protein deprived. JPEN J Parenter Enteral Nutr. 2013;37(3):300–9.)

. Ochoa Gautier JB, Martindale RG, Rugeles SJ, Hurt RT, Taylor B, Heyland DK, McClave SA. How much and what type of protein should a critically ill patient receive? Nutr Clin Pract. 2017;32(1_suppl):6S–14S.

. Weijs PJ, Stapel SN, de Groot SD, Driessen RH, Jong E, Girbes ARJ, et al. Optimal protein and energy mortality in mechanically ventilated critically ill patients: a prospective observational cohort study. J Parenter Enteral Nutr 2012;36:60e8.

. Singer P, Blaser AR, Berger MM, et al. ESPEN guideline on clinical in the intensive care unit. Clinical nutrition. 38: (2009); 48-79).

. Allingstrup MJ, Esmailzadeh N, Wilkens Knudsen A, Espersen K, Hartvig Jensen T, Wis J, et al. Provision of protein and energy in relation to measured requirements in intensive care patients. Clin Nutr 2012;31:462e8

. Song JH, Lee HS, Kim SY, Kim EY, Jung JY, Kang YA, et al. The influence of protein provision in the early phase of intensive care on clinical outcomes for critically ill patients on mechanical ventilation. Asia Pac J Clin Nutr 2017;26: 234e40.)

. Hoffer LJ, Bistrian BR. Appropriate protein provision in critical illness: a systematic and narrative review. Am J Clin Nutr. 2012 Sep;96(3):591-600. )

. Heyland DK, Cahill N, Day AG. Optimal amount of calories for critically ill patients: depends on how you slice the cake! Crit Care Med. 2011 Dec;39(12):2619-26.

. Zandarashvili L, Sahu D, Kwanbok L, et al. Real-time kinetics of high-mobility group box 1 (HMGB1) oxidation in extracellular fluids studied by in situ protein NMR spectroscopy. J Biol Chem. 2013 Apr 26; 288(17): 11621–11627.

. Lin WC, Chen CW, Chao L, et al. Plasma kallistatin in critically ill patients with severe sepsis and septic shock. PLoS One. 2017 May 24;12(5):e0178387

. Tiope Tl, Wu WKK, Chung L, et al. Plasminogen activator inhibitör 1 for predicting sepsis severity and mortality outcomes: A systematic review and meta- analysis. Fron Immunol.2018 Jun 18;9:1218.

. Ozsavci D, Ersahin M, Sener A, et al. The novel function of nesfatin-1 as anti- inflammatory and antiapoptotic peptide in subarachnoid hemorrhage-induced oxidative brain damage in ratr. Neurosurgery.2011 Jun;68(6):1699-708).

. Leivo-Korpela S, Lehtimäki L, Hämälainen M, Vuolteenaho K, Kööbi L, Järvenpää R, Kankaanranta H, Saarelainen S, Moilanen E. Adipokines NUCB2/nesfatin-1 and visfatin as novel inflammatory factors in chronic obstructive pulmonary disease. Mediators Inflamm. 2014; 2014: 232167.